ATE323702T1 - Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität - Google Patents

Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität

Info

Publication number
ATE323702T1
ATE323702T1 AT03766443T AT03766443T ATE323702T1 AT E323702 T1 ATE323702 T1 AT E323702T1 AT 03766443 T AT03766443 T AT 03766443T AT 03766443 T AT03766443 T AT 03766443T AT E323702 T1 ATE323702 T1 AT E323702T1
Authority
AT
Austria
Prior art keywords
tie2
tek
pyrimidines
activity
condensed pyridines
Prior art date
Application number
AT03766443T
Other languages
English (en)
Inventor
Richard William Arthur Luke
Clifford David Jones
William Mccoull
Barry Raymond Hayter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218168A external-priority patent/GB0218168D0/en
Priority claimed from GB0312356A external-priority patent/GB0312356D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE323702T1 publication Critical patent/ATE323702T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT03766443T 2002-08-06 2003-08-01 Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität ATE323702T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0218168A GB0218168D0 (en) 2002-08-06 2002-08-06 Compounds
GB0312356A GB0312356D0 (en) 2003-05-30 2003-05-30 Compounds

Publications (1)

Publication Number Publication Date
ATE323702T1 true ATE323702T1 (de) 2006-05-15

Family

ID=31497259

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03766443T ATE323702T1 (de) 2002-08-06 2003-08-01 Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität

Country Status (15)

Country Link
US (1) US7427616B2 (de)
EP (1) EP1537112B1 (de)
JP (1) JP2005538118A (de)
KR (1) KR20050067383A (de)
AR (1) AR041189A1 (de)
AT (1) ATE323702T1 (de)
AU (1) AU2003246972A1 (de)
BR (1) BR0313078A (de)
CA (1) CA2494421A1 (de)
DE (1) DE60304718T2 (de)
IL (1) IL166521A0 (de)
MX (1) MXPA05001389A (de)
NO (1) NO20050418L (de)
TW (1) TW200407116A (de)
WO (1) WO2004013141A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230089D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
GB0402518D0 (en) * 2004-02-05 2004-03-10 Astrazeneca Ab Therapeutic agents
JP4898458B2 (ja) * 2004-02-12 2012-03-14 トランス テック ファーマ，インコーポレイテッド 置換アゾール誘導体、組成物及び使用方法
CA2565037A1 (en) * 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
MXPA06013805A (es) 2004-05-27 2007-02-02 Pfizer Prod Inc Derivados de pirrolopirimidina de utilidad en el tratamiento contra el cancer.
CA2569887A1 (en) 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
BRPI0514094A (pt) * 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
SG155222A1 (en) 2004-08-13 2009-09-30 Genentech Inc Thiazole based inhibitors of atp-utilizing enzymes
WO2006076592A1 (en) 2005-01-14 2006-07-20 Cgi Pharmaceuticals, Inc. 1,3 substituted diaryl ureas as modulators of kinase activity
SI1962830T1 (sl) * 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
EP2038289A2 (de) 2006-04-21 2009-03-25 Amgen Inc. Thieno-[2,3-d]pyrimidin- und thieno-pyridazinverbindungen und anwendungsverfahren
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
EP2247596A2 (de) 2008-01-11 2010-11-10 Natco Pharma Limited Neuartige pyrazol-[3,4-d-]pyrimidin-derivate als wirkstoffe gegen krebs
EP2307456B1 (de) 2008-06-27 2014-10-15 Amgen Inc. Die inhibierung von ang-2 zur behandlung multipler sklerose
CA2731228A1 (en) 2008-07-22 2010-01-28 Biocryst Pharmaceuticals, Inc. Synthetic intermediates and processes
CA3121743A1 (en) 2009-01-15 2010-07-22 Incyte Holdings Corporation Processes for preparing jak inhibitors and related intermediate compounds
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
NZ602089A (en) 2010-02-17 2014-05-30 Takeda Pharmaceutical Heterocyclic compounds having cell division cycle 7 inhibitory activity
US8859768B2 (en) * 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
ES2533068T3 (es) 2010-09-08 2015-04-07 Bristol-Myers Squibb Company Nuevos análogos de piperazina como antivirales de influenza de amplio espectro
EA201390476A1 (ru) 2010-09-28 2013-08-30 Бристол-Майерс Сквибб Компани Новые пиперазиновые аналоги с замещенными гетероарильными группами в качестве противовирусных средств широкого применения против гриппа
WO2014079545A1 (en) * 2012-11-20 2014-05-30 Ktb Tumorforschungsgesellschaft Mbh Thioether derivatives as protein kinase inhibitors
EP2733146A1 (de) * 2012-11-20 2014-05-21 KTB Tumorforschungsgesellschaft mbH Thioetherderivate als Proteinkinase-Inhibitoren
JP2016529234A (ja) 2013-07-15 2016-09-23 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺有害生物化合物
CA2921199A1 (en) * 2013-08-27 2015-03-05 Bristol-Myers Squibb Company Ido inhibitors
US9777012B2 (en) 2014-12-17 2017-10-03 Duquesne University Of The Holy Spirit Substituted furo[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents
EP3632908A1 (de) 2018-10-02 2020-04-08 Inventiva Inhibitoren der yap / taz-tead-interaktion und ihre verwendung bei der behandlung von krebs
JP7629200B2 (ja) * 2018-11-20 2025-02-13 ジョージタウン ユニバーシティ 神経変性、筋変性及びリソソーム蓄積障害を治療するための組成物及び方法
EP4553080A1 (de) 2023-11-07 2025-05-14 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Nucleosidderivate als antivirale mittel gegen coronaviren

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD287503A5 (de) 1988-06-13 1991-02-28 Karl-Marx-Universitaet Leipzig,De Verfahren zur herstellung von 4-amino-2-mercapto-thieno-/2,3-d/pyrimidinen bzw. 4-amino-2-alkylthio-thieno/2,3-d/-pyrimidinen
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
EP0931152A2 (de) 1996-08-21 1999-07-28 Sugen, Inc. Kristallstrukturen einer protein-tyrosin kinase
DK0970084T3 (da) 1997-03-19 2003-09-29 Abbott Gmbh & Co Kg Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase
CA2309690A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO1999058523A1 (en) 1998-05-14 1999-11-18 G.D. Searle & Co. 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
CA2333770A1 (en) 1998-06-04 1999-12-09 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
CA2344262A1 (en) 1998-09-18 2000-03-30 Basf Aktiengesellschaft 4-aminopyrrolopyrimidines as kinase inhibitors
CA2344249A1 (en) 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines as protein kinase inhibitors
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
AR029347A1 (es) 1999-04-02 2003-06-25 Euro Celtique Sa Compuesto de adenina, compuesto de isognanina y 2,6-ditioxantina como precursor del mismo, uso de dichos compuestos para preparar una composicion farmaceutica y dicha composicion farmaceutica
WO2000059902A2 (en) 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company Aryl sulfonyls as factor xa inhibitors
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CA2385747A1 (en) 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
PL354241A1 (en) 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
JP2003509412A (ja) 1999-09-17 2003-03-11 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
TR200201364T2 (tr) 1999-11-22 2002-10-21 Smithkline Beecham P. L. C. Yeni bileşikler.
ATE345349T1 (de) 1999-12-17 2006-12-15 Ariad Pharma Inc Purinderivate
CA2394654A1 (en) 1999-12-17 2001-06-21 Manfred Weigele Proton pump inhibitors
EP1162196A4 (de) 1999-12-27 2003-04-16 Japan Tobacco Inc Verbindungen mit kondensierten ringen und ihre verwendung als medikamente
ATE322494T1 (de) 2000-01-07 2006-04-15 Universitaire Instelling Antwe Purin derivate, ihre herstellung und verwendung
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
MXPA02009543A (es) 2000-03-29 2005-08-26 Abbott Gmbh & Co Kg Metodo para identificar inhibidores de tie-2.
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
EP1345966A2 (de) 2000-09-08 2003-09-24 Glaxo Group Limited Kristallisierte zytoplasmatische tie2 rezeptor-tyrosinkinase domäne und verfahren zur feststellung und zum design ihrer modulatoren
WO2002039956A2 (en) 2000-11-15 2002-05-23 Rutgers, The State University Of New Jersey Black tea extract for prevention of disease
AU2002232439A1 (en) 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
US20030096813A1 (en) 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
AU2002333524A1 (en) 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
ATE404550T1 (de) 2001-09-21 2008-08-15 Smithkline Beecham Corp Chemische verbindungen
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
EP1456180B1 (de) 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
TW200306191A (en) 2002-02-22 2003-11-16 Teijin Ltd Pyrrolopyrimidine derivatives
EP1485390B1 (de) 2002-03-07 2008-10-08 F. Hoffman-la Roche AG Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase

Also Published As

Publication number Publication date
EP1537112B1 (de) 2006-04-19
AR041189A1 (es) 2005-05-04
DE60304718D1 (de) 2006-05-24
KR20050067383A (ko) 2005-07-01
US7427616B2 (en) 2008-09-23
JP2005538118A (ja) 2005-12-15
AU2003246972A1 (en) 2004-02-23
MXPA05001389A (es) 2005-04-28
US20050256140A1 (en) 2005-11-17
DE60304718T2 (de) 2007-04-26
NO20050418L (no) 2005-04-28
CA2494421A1 (en) 2004-02-12
EP1537112A1 (de) 2005-06-08
WO2004013141A1 (en) 2004-02-12
TW200407116A (en) 2004-05-16
IL166521A0 (en) 2006-01-15
BR0313078A (pt) 2005-07-12

Similar Documents

Publication Publication Date Title
ATE323702T1 (de) Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
ATE341546T1 (de) 4-trifluormethylpyrazolyl substituierte pyridine und pyrimidine
ATE472536T1 (de) Pyridin- und pyrimidin-derivate
IS6518A (is) Pyridín, pyrimidín, pyrazín og tríazín setin með arýl og notkun þeirra
PL375390A1 (en) 4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines
ATE402705T1 (de) Pyrimidine mit tie2 (tek) aktivität
ATE410429T1 (de) Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase
NO20021520L (no) Substituerte pyridiner og pyridaziner med angiogeneseinhiberende aktivitet
PL370480A1 (en) Aminopyrimidines and pyridines
NO20042676L (no) 3-beta-d-ribofuranolsyltiazolo[4,5-d]pyrimidinnukleosider og anvendelser derav
DE60217669D1 (de) Substitutierte pyrazinone, pyridine und pyrimidine als corticotropin-releasing-factor liganden
ATE415970T1 (de) Pyrimidine mit tie2 (tek) aktivität
ATE377591T1 (de) Pyrimidinderivate und deren verwendung als cb2- modulatoren
DE602004006383D1 (de) Die hiv-replikation inhibierende pyrimidine und triazine
HUP0401684A3 (en) Nicotinic acid-heterocyclyl-amides and analogous pyrimidine derivatives serving as pesticides
DK1480983T3 (da) Heteroarylsubstituerede 2-pyridinyl- og 2-pyrimidinyl- 6,7,8,9-tetrahydropyrimido[1,2a]pyrimidin-4-onderivater
DE69837621D1 (de) Substituierte pyrimidine und pyridine als unkrautbekämpfungsmittel
ATE340784T1 (de) Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden
ATE427748T1 (de) Pyridin-derivate und ihre verwendung als urotensin ii antagonisten
NO20035797L (no) 6-[2-(fosfonometoksy)alkoksy]pyrimidinderivater med antiviral aktivitet
ATE236124T1 (de) Herbizide 2,6-disubstituierte pyridine und 2,4- disubstituierte pyrimidine
ATE350370T1 (de) 2-substituierte pyrimidine
ZA200500863B (en) Condensed pyridines and pyrimidines with Tie2 (tek) activity.
DE60207280D1 (de) GLYCINSUBSTITUIERTE THIENO[2,3-d]PYRIMIDINE MIT KOMBINIERTER LH- UND FSH-AGONISTISCHER WIRKUNG
DE50106542D1 (de) Substituierte 3,4-dihydro-pyrido[1,2-a]pyrimidine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties